Medical Updates | Infection Update

MEDICAL UPDATES

Levofloxacin reduces mortality rate in myeloma

04 February, 2020

A randomised placebo-controlled trial that aimed to tackle early morbidity and mortality in myeloma (TEAMM) revealed that prophylactic levofloxacin reduces the risk of infection and death in patients with myeloma.1...

A randomised placebo-controlled trial that aimed to tackle early morbidity and mortality in myeloma (TEAMM) revealed that prophylactic levofloxacin reduces the risk of infection and death in patients with myeloma.1...

Sepsis: Early infectious disease consultation saves lives

27 December, 2019

A recent study on the acute management of patients with severe sepsis and septic shock revealed that infectious disease (ID) consultation within 12 hours after patients’ arrival at the hospital...

A recent study on the acute management of patients with severe sepsis and septic shock revealed that infectious disease (ID) consultation within 12 hours after patients’ arrival at the hospital...

The American Thoracic Society and Infectious Diseases Society of America update to the management of community-acquired pneumonia in adults – focus on antibiotic recommendations

16 December, 2019

The American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) have recently published an update to the previous guidelines on the management of community-acquired pneumonia (CAP) in adults.1,2...

The American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) have recently published an update to the previous guidelines on the management of community-acquired pneumonia (CAP) in adults.1,2...

Oral sitafloxacin vs intravenous ceftriaxone for the treatment of acute pyelonephritis and complicated urinary tract infection

An open-label randomised, controlled, noninferiority clinical trial has shown that oral sitafloxacin is noninferior to intravenous (IV) ceftriaxone followed by oral cefdinir for the treatment of acute pyelonephritis and complicated...

An open-label randomised, controlled, noninferiority clinical trial has shown that oral sitafloxacin is noninferior to intravenous (IV) ceftriaxone followed by oral cefdinir for the treatment of acute pyelonephritis and complicated...

Levofloxacin remains as one of the core agents in the treatment of tuberculosis

According to the current World Health Organization (WHO) guidelines (2016 update), fluoroquinolones including moxifloxacin, gatifloxacin, and levofloxacin are important second-line anti-tuberculosis (anti-TB) agents.1 A review of existing literature conducted by...

According to the current World Health Organization (WHO) guidelines (2016 update), fluoroquinolones including moxifloxacin, gatifloxacin, and levofloxacin are important second-line anti-tuberculosis (anti-TB) agents.1 A review of existing literature conducted by...

Oral levofloxacin and intravenous vancomycin for bacteraemia due to Microbacterium paraoxydans

A patient with bacteraemia associated with a long-term central venous catheter (CVC) due to Microbacterium paraoxydans responded well to replacement of CVC, and treatment with oral levofloxacin and intravenous vancomycin....

A patient with bacteraemia associated with a long-term central venous catheter (CVC) due to Microbacterium paraoxydans responded well to replacement of CVC, and treatment with oral levofloxacin and intravenous vancomycin....

Levofloxacin for lower lobe pneumonia presenting as persistent hiccups

Levofloxacin has been shown to resolve a case of community-acquired pneumonia in an elderly patient presenting with persistent hiccups – without any typical symptoms, signs, or laboratory findings of pneumonia....

Levofloxacin has been shown to resolve a case of community-acquired pneumonia in an elderly patient presenting with persistent hiccups – without any typical symptoms, signs, or laboratory findings of pneumonia....

Oral sitafloxacin as a switch therapy for the treatment of non-bacteraemic acute pyelonephritis

21 February, 2019

A treatment regimen of carbapenem followed by sitafloxacin or ertapenem was found to be effective in patients with non-bacteraemic acute pyelonephritis caused by extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC). The incidence...

A treatment regimen of carbapenem followed by sitafloxacin or ertapenem was found to be effective in patients with non-bacteraemic acute pyelonephritis caused by extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC). The incidence...

Managing mycobacterial infection after lung transplantation with levofloxacin: Case series

11 February, 2019

The combination of levofloxacin with isoniazid, pyrazinamide and ethambutol was found to be effective in managing mycobacterial infection in lung transplant recipients. The risk of mycobacterial infection is high for...

The combination of levofloxacin with isoniazid, pyrazinamide and ethambutol was found to be effective in managing mycobacterial infection in lung transplant recipients. The risk of mycobacterial infection is high for...

Levofloxacin improves spondylitis complication in Escherichia coli endocarditis

18 January, 2019

A two-month course of levofloxacin (500 mg/day) resolved purulent spondylitis in a patient with Escherichia coli infective endocarditis (IE). A 58-year old Japanese woman presented with febrile illness, malaise, and...

A two-month course of levofloxacin (500 mg/day) resolved purulent spondylitis in a patient with Escherichia coli infective endocarditis (IE). A 58-year old Japanese woman presented with febrile illness, malaise, and...

LATEST TOPICS